TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients

We intended to establish the frequency of exon‐specific TP53 gene alterations and the relation to patient and tumor characteristics and clinical outcome of patients with breast cancer. By using polymerase chain reaction‐single‐strand conformation polymorphism analysis (PCR‐SSCP) and sequencing techniques, TP53 gene alterations were found in 59 (32%) of the 187 samples studied. Most of the TP53 changes (37%) were observed in exon 7. In patients with known follow up (median, 107 months), there was no significant association of the frequency of TP53 mutation with menopausal or nodal status, tumor size, or progesterone receptor status. TP53 gene alterations were more frequently present in estrogen receptor (ER)‐negative (ER−) tumors (P = 0.04) and in tumors with an amplified HER2/NEU oncogene (P = 0.03). Univariate analysis showed that patients with a mutated TP53 in their primary tumors had shorter relapse‐free (P = 0.01) and overall (P = 0.03) survival. Patients with a TP53 gene mutation in exon 8 may be identified as having a particularly rapid rate of relapse. In Cox multivariate regression analysis, which included age, menopausal status, lymph node status, tumor size, steroid‐hormone‐receptor status, and oncogene amplifications, both TP53 gene alteration and MYC amplification independently predicted poor prognosis, with relative hazard rates for TP53 and MYC of 1.8 and 1.6, respectively, in analysis for relapse‐free survival and of 1.7 and 1.6, respectively, in analysis for overall survival. Genes Chromosom Cancer 16:170–179 (1996). © 1996 Wiley‐Liss, Inc.

[1]  L. Holmberg,et al.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.

[2]  E. Hovig,et al.  TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains , 1995, Genes, chromosomes & cancer.

[3]  J. Foekens,et al.  Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. , 1995, Gene.

[4]  L. Norton,et al.  p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[6]  J. Cunningham,et al.  p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. , 1995, Oncogene.

[7]  J. Eyfjörd,et al.  p53 abnormalities and genomic instability in primary human breast carcinomas. , 1995, Cancer research.

[8]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[9]  P. O'Connor,et al.  Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. , 1994, Science.

[10]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[11]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[12]  C. Prives.  How loops, β sheets, and α helices help us to understand p53 , 1994, Cell.

[13]  N F Cariello,et al.  Database and software for the analysis of mutations in the human p53 gene. , 1994, Cancer research.

[14]  S. Friend.  p53: a glimpse at the puppet behind the shadow play. , 1994, Science.

[15]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[16]  G. Hannon,et al.  The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA , 1994, Nature.

[17]  M. Oren.  Relationship of p53 to the control of apoptotic cell death. , 1994, Seminars in cancer biology.

[18]  W. Dupont,et al.  P53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment , 1994, Cancer.

[19]  C. Croce,et al.  Down-regulation of bcl-2 by p53 in breast cancer cells. , 1994, Cancer research.

[20]  N. Weidner,et al.  Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[22]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[23]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[24]  K. Heimdal,et al.  Prognostic significance of TP53 alterations in breast carcinoma. , 1993, British Journal of Cancer.

[25]  G. Merlo,et al.  In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high s‐phase index , 1993, International journal of cancer.

[26]  J. Foekens,et al.  Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[28]  Leland Hartwell,et al.  Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells , 1992, Cell.

[29]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[30]  A. Levine,et al.  Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. Theillet,et al.  p53 mutations occur in aggressive breast cancer. , 1992, Cancer research.

[32]  J. Bartek,et al.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. , 1992, Journal of immunological methods.

[33]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[34]  J. Marks,et al.  Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Foekens,et al.  c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. , 1992, Cancer research.

[36]  S. Sukumar,et al.  Mutations in p53 as potential molecular markers for human breast cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Carbone,et al.  Polymorphism at codon 213 within the p53 gene. , 1991, Oncogene.

[38]  J. Bartek,et al.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. , 1991, Oncogene.

[39]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[40]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[41]  H. J. Evans,et al.  Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. , 1990, Oncogene.

[42]  J. Foekens,et al.  Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. , 1989, Cancer research.

[43]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[44]  T. Sekiya,et al.  Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Shows,et al.  Transformation associated p53 protein is encoded by a gene on human chromosome 17 , 1985, Somatic cell and molecular genetics.

[46]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[47]  A. Harris.  p53 expression in human breast cancer. , 1992, Advances in cancer research.